North America Nuclear medicine Radiopharmaceuticals Industry Analysis, Size, Share, and Forecasts (2016–2021)
North America Nuclear medicine Radiopharmaceuticals Industry has been estimated at USD 1530 million in 2015 and is poised to reach USD 2600 million by 2020, growing at a CAGR of 11.2%.
(EMAILWIRE.COM, December 08, 2017 ) According to the report, The North America Nuclear medicine Radiopharmaceuticals Industry, published by Market Data Forecast. The Industry has been estimated at USD 1530 million in 2015 and is poised to reach USD 2600 million by 2020, growing at a CAGR of 11.2%. Nuclear medicine falls under the field of Molecular imaging, which involves usage of minute amount of radioactive material (radiopharmaceuticals) to diagnose and treat disease.
Browse Industry data tables and in-depth TOC of the North America Nuclear medicine Radiopharmaceuticals Industry to 2021 @ http://www.marketdataforecast.com/market-reports/north-america-nuclear-medicine-radiopharmaceuticals-market-129/
Increasing incidence of chronic diseases such as cancer and cardiac ailments, huge technological advancements, escalating demand for SPECT and PET applications along with the growing public awareness for healthcare are the major factors fuelling the growth of Radiopharmaceuticals Industry. Further, Integration of X ray tomography (CT) into SPECT has recently emerged as an excellent diagnostic tool in medical imaging and is considered to be a driving factor for the growth of the Industry. Strict regulatory framework and reimbursement issues are the key factors blocking the growth of the Industry. In addition to the above factors shorter half-life of radiopharmaceuticals and competition from orthodox diagnostic procedures are also the key factors restraining the North America nuclear medicine Radioisotopes Industry.
Download Free Sample Reports @ http://www.marketdataforecast.com/market-reports/north-america-nuclear-medicine-radiopharmaceuticals-market-129/request-sample
The Industry of radiopharmaceuticals is segmented into Diagnostic radioisotopes and Therapeutic radioisotopes. Diagnostic radioisotope Industry basically covers SPECT (Technetium-99m, Thallium-201 Gallium-67, Iodine) and PET (Fluorine-18, Rubidium-82) radioisotopes. Therapeutic radioisotopes cover Beta emitters (Iodine-131, Yttrium-90, Samarium-153, Rhenium-186, Lutetium-177), Alpha Emitters (Radium-223) and Brachytherapy (Cesium-131, Iodine-125, Palladium-103, Iridium-192). By application Industry is segmented into (cardiology, lymphoma, thyroid, neurology oncology, and others). Furthermore, on the basis of geography, the North America Industry is analyzed two regions namely, USA and Canada.
Key Points from Table of Contents
• Overview
o Executive Summary
o Key Inferences
o New Developments
• Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
o Industry Segmentation
o By Type
o By Therapeutic Radioisotopes
o By Application
• Geographical Analysis
• Pipeline Product Analysis
o Strategic Analysis
o PESTLE analysis
o Porter’s Five analysis
• Industry Leaders' Analysis
• Competitive Landscape
Radiopharmaceuticals Industry is dominated by diagnostic radioisotopes with an estimated Industry share of 90 % while therapeutic radioisotopes contribute for around 10% of the Industry. Based on type of radioisotopes the Industry is segmented into Technetium-99m (TC-99m), Thallium-201 (TL-201), Fluorine-18, Iodine (I-123), Rubidium-82 (RB-82) and others. The F-18 Industry is mostly contributed by F-18 FDG tracers though this Industry is enriched with future tracers such as F-18 Florbetapir and F-18 Choline. The promising clinical outcomes of these tracers have gained the business interest of major research institutes and PET isotope players. Ga-68 and Rb-82 are two other potential isotopes in the PET diagnostic Industry, ensuring high growth of the diagnostics segment. Diagnosis of coronary artery disease, bone metastasis, and Alzheimer’s disease are the most promising indications for the future PET radioisotopes Industry. United States is the largest consumer Industry for radioisotopes and Canada is the largest producer of Tc-99m.
Customization Report @ http://www.marketdataforecast.com/market-reports/north-america-nuclear-medicine-radiopharmaceuticals-market-129/customize-report
Some of the key players influencing the North America nuclear medicine Industry are GE Healthcare, Hologic Inc., Medix Inc., Segami Corporation,Positron Corporation,Bracco Imaging S.p.A, Naviscan Inc., Bayer Healthcare, Lantheus Medical Imaging, Inc. and IBA Molecular Imaging.
About Market Data Forecast:
Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, they cater to the needs of both individual and corporate clients. From all-encompassing umbrella markets to extremely specific niche markets covering all the major regions across the globe as part of the research scope, their research services offer one of a kind specialities with competitive pricing options. For more info kindly visit, www.marketdataforecast.com
Browse Industry data tables and in-depth TOC of the North America Nuclear medicine Radiopharmaceuticals Industry to 2021 @ http://www.marketdataforecast.com/market-reports/north-america-nuclear-medicine-radiopharmaceuticals-market-129/
Increasing incidence of chronic diseases such as cancer and cardiac ailments, huge technological advancements, escalating demand for SPECT and PET applications along with the growing public awareness for healthcare are the major factors fuelling the growth of Radiopharmaceuticals Industry. Further, Integration of X ray tomography (CT) into SPECT has recently emerged as an excellent diagnostic tool in medical imaging and is considered to be a driving factor for the growth of the Industry. Strict regulatory framework and reimbursement issues are the key factors blocking the growth of the Industry. In addition to the above factors shorter half-life of radiopharmaceuticals and competition from orthodox diagnostic procedures are also the key factors restraining the North America nuclear medicine Radioisotopes Industry.
Download Free Sample Reports @ http://www.marketdataforecast.com/market-reports/north-america-nuclear-medicine-radiopharmaceuticals-market-129/request-sample
The Industry of radiopharmaceuticals is segmented into Diagnostic radioisotopes and Therapeutic radioisotopes. Diagnostic radioisotope Industry basically covers SPECT (Technetium-99m, Thallium-201 Gallium-67, Iodine) and PET (Fluorine-18, Rubidium-82) radioisotopes. Therapeutic radioisotopes cover Beta emitters (Iodine-131, Yttrium-90, Samarium-153, Rhenium-186, Lutetium-177), Alpha Emitters (Radium-223) and Brachytherapy (Cesium-131, Iodine-125, Palladium-103, Iridium-192). By application Industry is segmented into (cardiology, lymphoma, thyroid, neurology oncology, and others). Furthermore, on the basis of geography, the North America Industry is analyzed two regions namely, USA and Canada.
Key Points from Table of Contents
• Overview
o Executive Summary
o Key Inferences
o New Developments
• Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
o Industry Segmentation
o By Type
o By Therapeutic Radioisotopes
o By Application
• Geographical Analysis
• Pipeline Product Analysis
o Strategic Analysis
o PESTLE analysis
o Porter’s Five analysis
• Industry Leaders' Analysis
• Competitive Landscape
Radiopharmaceuticals Industry is dominated by diagnostic radioisotopes with an estimated Industry share of 90 % while therapeutic radioisotopes contribute for around 10% of the Industry. Based on type of radioisotopes the Industry is segmented into Technetium-99m (TC-99m), Thallium-201 (TL-201), Fluorine-18, Iodine (I-123), Rubidium-82 (RB-82) and others. The F-18 Industry is mostly contributed by F-18 FDG tracers though this Industry is enriched with future tracers such as F-18 Florbetapir and F-18 Choline. The promising clinical outcomes of these tracers have gained the business interest of major research institutes and PET isotope players. Ga-68 and Rb-82 are two other potential isotopes in the PET diagnostic Industry, ensuring high growth of the diagnostics segment. Diagnosis of coronary artery disease, bone metastasis, and Alzheimer’s disease are the most promising indications for the future PET radioisotopes Industry. United States is the largest consumer Industry for radioisotopes and Canada is the largest producer of Tc-99m.
Customization Report @ http://www.marketdataforecast.com/market-reports/north-america-nuclear-medicine-radiopharmaceuticals-market-129/customize-report
Some of the key players influencing the North America nuclear medicine Industry are GE Healthcare, Hologic Inc., Medix Inc., Segami Corporation,Positron Corporation,Bracco Imaging S.p.A, Naviscan Inc., Bayer Healthcare, Lantheus Medical Imaging, Inc. and IBA Molecular Imaging.
About Market Data Forecast:
Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, they cater to the needs of both individual and corporate clients. From all-encompassing umbrella markets to extremely specific niche markets covering all the major regions across the globe as part of the research scope, their research services offer one of a kind specialities with competitive pricing options. For more info kindly visit, www.marketdataforecast.com
Contact Information:
Market Data Forecast.
Abhishek
Tel: +1-888- 702-9626
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
Market Data Forecast.
Abhishek
Tel: +1-888- 702-9626
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results